Epimacular brachytherapy reduces re-treatment for up to 2 years

Epimacular brachytherapy safely reduced ranibizumab re-treatments for up to 1 year in patients with neovascular age-related macular degeneration, according to a study.The MERITAGE trial included 53 patients previously treated for neovascular AMD who underwent pars plana vitrectomy with a single dose of epimacular brachytherapy and subsequent monthly re-treatment with ranibizumab as needed. Two-year data included 47 patients.

Full Story →